AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03329313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lowering sodium concentration dialysate
Description: Concentration of sodium in dialysate at 140 mmol/l
Study NCT03329313 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Highing sodium concentration dialysate
Description: Concentration of sodium in dialysate at 145 mmol/l
Study NCT03171558 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric Pull Up
Description: Using gastric tissue to reconstruct the esophagus and pharynx after pharyngo-esophagectomy.
Study NCT03171558 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free Flap Surgery
Description: Using radial forearm free flap or anterolateral thigh free flap to reconstruct the cervical esophagus and pharynx after pharyngectomy and cervical esophagectomy.
Study NCT04842396 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental:Motorized cycle ergometer
Description: Cycling training on the MOTOmed Muvi for 20 minutes 3 days per week for 6 weeks. Moreover, control of adverse events throughout the trial was measured through the assessment and monitoring of vital signs before, during (within the first 10 minutes), and after the intervention sessions. Vital signs \[heart rate (per minute), systolic and diastolic blood pressure (in millimeters of mercury, mm Hg), and oxygen saturation (in percentage)\] were monitored by a nurse and a medical doctor using mobile finger pulse oximeters.
Study NCT02947607 — intervention group
Intervention type: PROCEDURE
Intervention: Colon biopsies
Study NCT02488382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lonquek
Description: Patients will be given a single fixed dose of Lonquek (Teva LTD), 12-mg subcutaneously.
Study NCT02654795 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: CT angiography will be performed with a dual-source CT scanner using prospective ECG gating, with detector collimation of 128x0.6 mm, a gantry rotation time of 280 ms, tube voltage of 100-120 kV, tube current of 280-380 mAs depending on the patient's body mass.
Study NCT02654795 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: computed tomography
Description: CT angiography will be performed with a dual-source CT scanner using prospective ECG gating, with detector collimation of 128x0.6 mm, a gantry rotation time of 280 ms, tube voltage of 100-120 kV, tube current of 280-380 mAs depending on the patient's body mass.
Study NCT00910806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC207; nevirapine
Study NCT00671996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mangafodipir
Description: Treatment will be undertaken with a ready-to-use investigative drug formulation identical to what is in diagnostic use as a contrast medium for MRI.~Formulation content: MnDPDP 10 mmol/ml~Administered dose per cycle: 2 μmol/kg b.w. Administration form: Ready-to-use formulation (solution). Mangafodipir or placebo (0.2 ml/kg b.w.) will be administered as an i.v. infusion over 5 min about 30 min prior to start of chemotherapy.
Study NCT00671996 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment (0.9% NaCl)
Description: Intravenous infusion, 2 micromol/kg, pretreatment 30 minutes before the start of FOLFOX treatment (during the first three FOLFOX treatments)
Study NCT04374500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leptin infusion plus vasodilators in healthy men
Description: This applies only to protocol 2 with two arms (leptin or saline) where four vasodilatators (bradykinin, acetylcholine, sodium nitroprusside and verapamil) were infused concomitantly
Study NCT04374500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leptin infusion in healthy men
Description: This applies only to protocol 1 when only leptin was given
Study NCT04374500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasodilators in CAD patients
Description: This applies only to protocol 3
Study NCT02053194 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist-led educational intervention
Description: 1) Educational material to participants in the form of a written educational brochure on inappropriate prescriptions that was developed and tested during the EMPOWER study. 2) Evidence-based pharmaceutical opinions sent to the treating physicians.
Study NCT04293809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel Injectable Product
Description: bupivacaine liposome injectable suspension
Study NCT04293809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: 1.3%, 13.3 mg/mL
Study NCT03539029 — intervention group
Intervention type: PROCEDURE
Intervention: Conservative treatment
Description: immobilisation with plaster cast
Study NCT01914965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: Crossover design: Oral administration of 150 mg bupropion once daily for 2 weeks, followed by 300 mg bupropion once daily for subsequent 8 weeks, tapering: 150 mg bupropion once daily for 7 days
Study NCT01914965 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupropion
Description: Crossover design: Oral administration of 150 mg bupropion once daily for 2 weeks, followed by 300 mg bupropion once daily for subsequent 8 weeks, tapering: 150 mg bupropion once daily for 7 days
Study NCT01914965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Crossover design: Oral administration of placebo once daily for 2 weeks, followed by placebo once daily for subsequent 8 weeks, tapering: placebo once daily for 7 days
Study NCT01914965 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Crossover design: Oral administration of placebo once daily for 2 weeks, followed by placebo once daily for subsequent 8 weeks, tapering: placebo once daily for 7 days
Study NCT00275015 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00275015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Study NCT03534011 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resuscitative Balloon Occlusion of the Aorta
Description: If return of spontaneous circulation (ROSC) is not achieved after advanced cardiac life support (ACLS) is established, a REBOA catheter is inserted via the femoral artery and the aortic balloon inflated, according to a procedure described in a separate document. Ultrasound is used to limit risk related to cannulation and placement of the guidewire.
Study NCT03534011 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REBOA catheter
Description: Catheter with a Resuscitative Balloon for Occlusion of the Aorta
Study NCT04860856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Description: The maximal single dose of ropivacaine without vasoconstrictor is 2-3 mg/kg.9 0.5% ropivacaine has 5 mg/mL of ropivacaine. 20 mL of 0.5% ropivacaine has 100 mg of ropivacaine. 100 mg of ropivacaine can be toxic to a patient less than 33-50 kg or 73-110 lb. If a patient weighs less than 110 lb, the ropivacaine dose will be scaled down below 2 mg/kg.
Study NCT04860856 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 20ml of normal saline
Study NCT01547221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clotrimazole
Description: single application of 1%clotrimazole ear drop
Study NCT01547221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3% Boric acid
Description: 3% boric acid in 70% alcohol was prepared by phamaceutical department of Khonkaen Hospital
Study NCT00826228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teriparatide
Description: teriparatide 20ug daily sc for 6 months
Study NCT00826228 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: weight-bearing
Description: device assisted walking
Study NCT01782729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus ointment, 0.03 percent twice a day for pediatric population for 4 weeks or until 1 week after the affected areas defined for treatment at baseline are completely cleared, whichever is first.
Study NCT00113269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: basiliximab
Description: IV
Study NCT00113269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rabbit anti-thymocyte globulin
Description: IV
Study NCT00113269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: oral
Study NCT00113269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: oral
Study NCT00113269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Description: Intravenous (IV)
Study NCT00113269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: oral
Study NCT00113269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil
Description: oral
Study NCT00113269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: steroids
Description: IV and/or oral
Study NCT00113269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: steroids
Description: IV and/or oral
Study NCT04596176 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Program Supportive Housing Services
Description: The existing statewide SH model that included routine access to housing (voucher) and case management
Study NCT04596176 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Supportive Housing Services
Description: an intensive treatment SH model with a higher dosage of case management, family teaming, and access to a vocational specialist
Study NCT00514800 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention - a validated home BP monitor and support from the specialist nurse
Study NCT00514800 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control - usual care (BP monitoring by their practice)
Description: Patients will not receive a blood pressure monitor and will continue with usual GP care for hypertension management.~GPs will be sent information about the study design, current guidelines and interpretation of home blood pressure readings.
Study NCT03767972 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Energy-based device
Description: Patients will receive one treatment for rejuvenation using one or multiple energy-based devices based on investigator discretion.
Study NCT04290611 — intervention group
Intervention type: DRUG
Intervention: Enzalutamide
Description: Enzalutamide for the treatment of prostate cancer or other solid tumors
Study NCT02071680 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Iodine-123 Meta-iodobenzylguanidine
Description: A single injection of the 123I-mIBG will be given. Imaging will be done twice following injection: at 0120 minutes and 3-5 hours. The timing is dependent on the specific participant and imaging characteristics.~The imaging is done for approximately 24 minutes at each time point.
Study NCT02851849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LGD-6972-5 mg
Description: 5 mg LGD-6972 QD
Study NCT02851849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LGD-6972-10 mg
Description: 10 mg LGD-6972 QD
Study NCT02851849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LGD-6972-15 mg
Description: 15 mg LGD-6972 QD
Study NCT02851849 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo QD
Study NCT03840356 — intervention group
Intervention type: OTHER
Intervention: Postoperative
Description: No intervention is planned in the study. This study is simply evaluating the consistency with which patients report their pain levels to different members of the medical team.
Study NCT00853372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib will be administered 50 mg QD and is considered to be the background therapy as it is licensed for treatment of reneal cell cancer (RCC) and will be administered to all participants.
Study NCT00853372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trebananib
Description: Administered until a participant develops disease progression, clinical progression, unacceptable toxicity, withdraws consent, or death.
Study NCT03631303 — intervention group
Intervention type: DEVICE
Intervention: Cardiac stimulation through the device leads
Description: During scheduled device replacement extra-systolic beats with various extrasystolic and post-extrasystolic coupling intervals will be evoked by electrical stimulation via the right atrial and ventricular device leads of the patient. Throughout the stimulation study blood pressure will be measured non-invasively using a finger arterial blood pressure photoplethysmographic device and a continuous electrocardiogram will be recorded.
Study NCT01130311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
Study NCT01130311 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline injection
Description: normal saline, intramuscular preperation,given in 2 doses at week 0 and week 4 of trial
Study NCT03320395 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Small bowel RFA treatment
Description: The samples will be spread and fixed using needles. The prototype RFA-SB ablation catheter will be applied by the PI as follows to each section of duodenum, jejunum and ileum.~The treating paddle of the prototype RFA-SB catheter will be pushed on the small bowel mucosa exerting the same pressure that would be applied endoscopically.~12 J/cm2 will be applied every time with a 20 second interval between applications to simulate clinical practice.~There will be two single applications to two separate specimen sites. There will be two double applications to two separate specimen sites. There will be two triple applications to two separate specimen sites. There will be two quadruple applications to two separate specimen sites.
Study NCT00275015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00275015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Study NCT00275015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Study NCT00275015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT00275015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Study NCT00275015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Study NCT00275015 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow ablation with stem cell support
Study NCT00275015 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study NCT00275015 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT02982148 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: methylene blue intradermal injection
Description: Methylene blue has been prove to be effective and safe as a blue dye for sentinel lymph node biopsy in early breast cancer patient. But it was also reported by some article that adverse skin lesions appeared after methylene blue injections for sentinel lymph node localization. But the effectiveness and safety of methylene blue intradermal injection has not yet been investigated.
Study NCT02982148 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: methylene blue subcutaneous injection
Description: Methylene blue subcutaneous injection has become one of the standard method for sentinel lymph node biopsy for breast cancer patients. In such case, we use this method to be an active comparator for the intradermal injection group.
Study NCT01575002 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Subjects will undergo 2 sessions of 20 minutes of tDCS stimulation (either active or sham)in a randomized order - each session will be separated by at least one week to prevent carry-over effects.
Study NCT01575002 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: Subjects will undergo 2 sessions of 20 minutes of tDCS stimulation (either active or sham)in a randomized order - each session will be separated by at least one week to prevent carry-over effects.
Study NCT00846690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: benzocaine
Description: 20% benzocaine., topical placement onto site, minimal amount, for 1 minute
Study NCT00846690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAC alternate gel
Description: use 1 pump, place topically onto site, leave for 1-3 minutes
Study NCT04633291 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel swelling media
Description: Intermittent catheterization through the urethra draining the bladder, performed by a trained nurse.
Study NCT04633291 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparator swelling media
Description: Intermittent catheterization through the urethra draining the bladder, performed by a trained nurse.
Study NCT00851864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinzaparin
Description: LMWH (tinzaparin-Innohep, Leo Pharma A/S) 175 anti-factor Xa units per kilogram of body weight sub-cutaneously once daily.~Treatment will be done for the duration of the pregnancy.
Study NCT01858025 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pencil Beam scanning Radiation
Study NCT01858025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Study NCT01858025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin-C
Study NCT02104167 — intervention group
Intervention type: DEVICE
Intervention: ROIC interbody cage with VerteBRIDGE plating
Study NCT01030354 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Herbalife Meal Replacements
Description: Higher protein meal replacement diet based on 1 gram of protein per pound of lean body mass will improve weight loss in comparison to a standard protein meal replacement diet based on ½ gram of protein per pound of lean body mass
Study NCT01030354 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Herbalife Meal Replacements
Description: Higher protein meal replacement diet based on 1 gram of protein per pound of lean body mass will improve weight loss in comparison to a standard protein meal replacement diet based on ½ gram of protein per pound of lean body mass.
Study NCT02143934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine
Study NCT02143934 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pills, appearance identical to Primaquine tablets
Study NCT02143934 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chloroquine
Study NCT02143934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Study NCT02143934 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Artemether Lumefantrine
Study NCT02143934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether Lumefantrine
Study NCT03126123 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: acetic acid test
Description: Patients will receive acetic acid on the mucosa of the anal canal before the surgical procedure
Study NCT01068587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MET/VEGFR2 inhibitor Foretinib
Description: PhaseI and Phase II Arm A:~Foretinib PO daily dosing starting cycle 1 day 15 and erlotinib PO daily dosing starting cycle 1 day 1. Recommended Phase II dose to be determine in Phase I.
Study NCT01068587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erlotinib hydrochloride
Description: erlotinib PO daily dosing starting cycle 1 day 1. Recommended Phase II dose to be determine in Phase I.
Study NCT01068587 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Tumour markers alone cannot be used to assess objective tumour response. If markers are initially above the upper normal limit, however, they must normalize for a patient to be considered in complete response
Study NCT04571385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP30663
Description: Administer by intravenous infusion.
Study NCT04571385 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to AP30663.
Study NCT00932386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hcl infusion
Description: 0.5mcg/kg/hr
Study NCT00932386 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 0.9% normal saline infusing
Study NCT04145388 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: online cancer risk assessment
Description: Electronic surveys to collect family cancer history information.
Study NCT04145388 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Family cancer history captured by provider during a clinical encounter
Study NCT01387945 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HBPM+website+patient navigator
Description: In addition to home blood pressure monitor, patient receives access to BP web portal and trained patient navigator.